Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tashkent Political Wire.
Press releases published on October 20, 2025
ROSEN, A LEADING LAW FIRM, Encourages Fortinet, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTNT
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Fortinet, Inc. (NASDAQ: FTNT) between November 8, 2024 and August 6, 2025, both dates inclusive (the “Class Period”), …
RZLV Investor News: If You Have Suffered Losses in Rezolve AI plc (NASDAQ: RZLV), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Rezolve AI plc (NASDAQ: RZLV) resulting from allegations that Rezolve …
DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of …
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that …
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that …
ROSEN, A RESPECTED AND LEADING FIRM, Encourages RCI Hospitality Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – RICK
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 and September 16, 2025, both dates inclusive ( …
SMTC Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Semtech Corporation – SMTC
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Semtech Corporation (NASDAQ: SMTC). If you currently own …
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRX
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, …
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Quantum Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - QMCO
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quantum Corporation (NASDAQ: QMCO) between November 15, 2024 and August 18, 2025, inclusive (the “Class Period”), of the …
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings …